Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.